S& 500 rise on U.S.-Japan trade deal optimism; Tesla, Alphabet earnings due
Benjamin Landry, the General Counsel of Health Catalyst , Inc. (NASDAQ:HCAT), recently executed a sale of company shares. According to a Form 4 filing with the Securities and Exchange Commission, Landry sold 13,827 shares of Health Catalyst common stock on March 6, 2025. The shares were sold at an average price of $4.5462 per share, resulting in a total transaction value of $62,860. The sale comes as the stock trades near its 52-week low of $3.76, having declined about 45% over the past six months. InvestingPro analysis suggests the stock is currently undervalued, with analysts projecting profitability this year despite recent challenges.
Following this transaction, Landry holds 160,437 shares in the company. The sale was conducted under a pre-arranged trading plan established on March 1, 2024, in accordance with Rule 10b5-1, a regulation that allows company insiders to set up a predetermined plan to sell stocks. For deeper insights into insider trading patterns and comprehensive valuation metrics, explore the detailed Health Catalyst Pro Research Report, available exclusively on InvestingPro.
In other recent news, Health Catalyst Inc. reported its fourth-quarter 2024 financial results, revealing an earnings miss with an EPS of -$0.33 against a forecast of $0.07. Revenue for the quarter was $79.6 million, slightly below the expected $80.68 million. The company saw a 6% year-over-year increase in fourth-quarter revenue, driven by a 10% growth in technology revenue, while professional services revenue remained flat. Despite the earnings miss, Health Catalyst’s adjusted EBITDA for the quarter surged by 485% year-over-year to $7.9 million. The company has set ambitious guidance for 2025, anticipating revenue of approximately $335 million and an adjusted EBITDA of about $41 million. BTIG analysts have revised the price target for Health Catalyst shares to $10 from $13, maintaining a Buy rating. This adjustment follows the company’s earnings report and reflects lower-than-expected service adjusted gross margins. Health Catalyst continues to phase out lower-margin agreements, aiming to improve margins as the year progresses.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.